Abstract
Background -The aim of this study was to compare the systemic bioactivity of inhaled budesonide (B) and fluticasone propionate (F), each given by large volume spacer, on a microgram equivalent basis in asthmatic children. Methods -Ten stable asthmatic children of mean age 11 years and forced expiratory volume in one second (FEV1) 81 .6% predicted, who were receiving treatment with s400 ig/day of inhaled corticosteroid, were studied in a placebo controlled single blind (investigator blind) randomised crossover design comparing single doses of inhaled budesonide and fluticasone propionate 400 tg, 800 ftg, and 1250 pg. Doses were given at 20.00 hours with mouth rinsing and an overnight 12 hour urine sample was collected for estimation of free cortisol and creatinine excretion.
Results -The results of overnight 12 4 it is clear that, when using a large volume spacer, the main determinant of overall systemic bioavailability will be the lung bioavailability which avoids first pass hepatic metabolism for both fluticasone and budesonide. ' Although systemic side effects from inhaled corticosteroids are not considered a problem at doses up to 400 gg/day, it is not uncommon for asthmatic children to require higher doses to maintain control of their disease. The aim of this study was to compare the systemic bioactivity of single doses of budesonide and fluticasone propionate given by large volume spacer to asthmatic children. As far as we are aware, no dose-ranging studies have previously addressed this issue in children.
Methods

PATIENTS
Ten asthmatic children (outpatients, two girls) of mean (SD) age 11 (2.11) years (range [8] [9] [10] [11] [12] [13] [14] completed the study. The mean forced expiratory volume in one second (FEVI) was 81.6 (6.26)% predicted (range 72-91% predicted) and mid forced expiratory flow (FEF25-75) was 74.8 (16.5)% predicted. All were using inhaled corticosteroids in a dose of < 400 jg/day: beclomethasone dipropionate 200 jig/day (two children), 300 jg/day (one child), 400 jig/day (three children); budesonide 400 jig/day (two children), and fluticasone propionate 200 jig/day (two children). None had received oral corticosteroids in the preceding three months.
Both parents and children gave written informed consent. Approval for the study was obtained from the Tayside medical ethics committee for measurement of overnight In adult studies budesonide delivered by Nebuhaler causes increased adrenal suppression compared with metered dose inhaler alone.'4 This presumably reflects the effect of enhanced lung bioavailability with the spacer which outweighs the effect of reduced oral bioavailability, at least for budesonide where first pass metabolism is 89%. The present finding of adrenal suppression caused by single doses of inhaled fluticasone compared with budesonide, using a large volume spacer and mouth rinsing, further highlights the point that lung bioavailability is also the determinant of its systemic bioactivity in asthmatic children.
In conclusion, our study provides clear evidence of adrenal suppression with single doses of inhaled fluticasone propionate given by spacer to asthmatic children. It is likely that, with repeated dosing, the differences between fluticasone and budesonide would be greater'5 due to the longer plasma half life and receptor binding affinity as well as enhanced systemic tissue retention for fluticasone than for budesonide. Further chronic dose ranging studies are now indicated to resolve this issue.
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